APA (7th ed.) Citation

Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., . . . Lindemann, K. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial. Lancet, 403(10434), 1341. https://doi.org/10.1016/S0140-6736(24)00317-9

Chicago Style (17th ed.) Citation

Lorusso, Domenica, et al. "Pembrolizumab or Placebo with Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomised, Double-blind, Phase 3 Clinical Trial." Lancet 403, no. 10434 (2024): 1341. https://doi.org/10.1016/S0140-6736(24)00317-9.

MLA (9th ed.) Citation

Lorusso, Domenica, et al. "Pembrolizumab or Placebo with Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomised, Double-blind, Phase 3 Clinical Trial." Lancet, vol. 403, no. 10434, 2024, p. 1341, https://doi.org/10.1016/S0140-6736(24)00317-9.